INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity
Covered in this story
What has happened since
- Inmune Bio Inc is down 34.6% since this was published, 55 days ago.
- Mid-America Apartment Communities is down 10.8% since this was published, 55 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $INMB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Inmune Bio Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.